Fengshan Wang

Anticancer polysaccharides from natural resources: A review of recent research

Taking into account the rising trend of the incidence of cancers of various organs, effective therapies are urgently needed to control human malignancies. However, almost all of the chemotherapy drugs currently on the market cause serious side effects. Fortunately, several previous studies have shown that some non-toxic biological macromolecules, including polysaccharides and polysaccharide-protein complexes, possess anti-cancer activities or can increase the efficacy of conventional chemotherapy drugs. Based on these encouraging observations, a great deal of effort has been focused on discovering anti-cancer polysaccharides and complexes for the development of effective therapeutics for various human cancers. This review focuses on the advancements in the anti-cancer efficacy of various natural polysaccharides and polysaccharide complexes in the past 5 years. Most polysaccharides were tested using model systems, while several involved clinical trials.

Isolation, structural characterization and immunological activity of an exopolysaccharide produced by Bacillus licheniformis 8-37-0-1

A strain of Bacillus licheniformis 8-37-0-1 with high exopolysaccharide (EPS) production ability was isolated and identified based on morphological and physiological characteristics and phylogenetic analysis of 16S rDNA sequences. A new type of EPS was isolated from the strain fermentation broth by enzymolysis, isopropanol precipitation, anion-exchange, and gel-filtration chromatography. The new EPS was determined as homogeneous, with a molecular weight of 2.826 x 10(4), as determined by High-Performance Size-Exclusion Chromatography Multi-Angle Laser Light Scattering analysis. Its structural characteristics were investigated and elucidated by methylation analysis, partial acid hydrolysis, gas-liquid chromatography mass spectrometry, Fourier transform infrared, and nuclear magnetic resonance spectroscopy. Based on obtained data, the EPS was found to be a levan containing a (2-->6)-linked backbone with a single beta-d-fructose at the C-1 position every seven residue, on average, along the main chain. Preliminary in vitro tests revealed that EPS could significantly stimulate the proliferation of spleen lymphocyte.

Structural characterisation and antimutagenic activity of a novel polysaccharide isolated from Sepiella maindroni ink

A new heteropolysaccharide, named as SIP, was isolated from the ink of cuttlefish, Sepiella maindroni, by enzymolysis, anion-exchange and gel-permeation chromatography and tested for its antimutagenic activity. It was homogeneous with a molecular weight of 1.13×10(4)Da by HPSEC-MALLS analysis. SIP contained glucuronic acid, mannose, N-acetylgalactosamine, and fucose in a molar ratio of 1:1:2:2. Its structural characteristics were investigated and elucidated by methylation analysis, GLC-MS, and NMR ((1)H, (13)C, H-H COSY, HMQC, HMBC, TOCSY and NOESY). The hexasaccharide repeating unit of SIP was found to be a backbone composed of fucose, N-acetylgalactosamine and mannose in a molar ratio of 2:2:1, and with a single branch of glucuronic acid at the C-3 position of mannose. According to the micronucleus test, SIP could significantly reduce the frequency of micronucleated cells in polychromatic erythrocytes and reticulocytes induced by cyclophosphamide in tumor-bearing mice, which revealed that SIP presented strong antimutagenic activity.

Immunomodulatory activity of polysaccharides isolated from Strongylocentrotus nudus eggs.

Our previous work showed that SEP, a novel glucan isolated from the eggs of sea urchins, Strongylocentrotus nudus, had remarkable anti-tumor activity. To elucidate the mechanism of the anti-tumor activity, the immunomodulatory activity of SEP was investigated. The in vivo experiment results showed that SEP remarkably enhanced spleen and thymus index in S180-bearing mice, and also stimulated ConA-induced splenocyte proliferation. Immunomodulatory activity assay in vitro indicated SEP could significantly enhance the mouse splenocyte proliferation in a dose-dependent manner. According to comitogenic activity tests, SEP showed significant comitogenic activities and adjuvant properties. We also demonstrated that SEP had a unique mode of immunostimulation with regard to its cell-type specificity. In other words, SEP markedly stimulated B and T cell proliferation, however the influence on B cells was greatly weaker than that on T cells. IL-2, TNF-alpha, and IFN-gamma mRNA expression was upregulated after the mouse splenocytes were treated by SEP, indicating that Th1 cell was the primary cellular target affected by SEP on T lymphocyte. SEP enhanced production of nitric oxide (NO), upregulated mRNA expression of inducible nitric oxide synthase (iNOS) in peritoneal macrophages in a dose-dependent manner. In addition, SEP did not show direct toxicity to tumor cells. Consequently, the anti-tumor effect of SEP was related to stimulating host immunity/enhancing the immune system functions, which may mainly result from SEP activating lymphocytes and macrophages and stimulating secretion of some cytokines.

Anti-metastatic and anti-angiogenic activities of sulfated polysaccharide of Sepiella maindroni ink.

A previous study demonstrated that SIP-SII, a sulfated Sepiella maindroni ink polysaccharide, suppressed the invasion and migration of cancer cells via the inhibition of the proteolytic activity of matrix metalloproteinase-2 (MMP-2). Therefore, this study investigated the anti-metastatic effect of SIP-SII in vivo. SIP-SII (15 and 30 mg/kg d) markedly decreased B16F10 pulmonary metastasis in mice models by 85.9% and 88.0%, respectively. Immunohistochemistry showed that SIP-SII decreased the expression of the intercellular adhesion molecule 1 (ICAM-1) and basic fibroblast growth factor (bFGF) in lung metastasis nodules. In addition, SIP-SII inhibited neovascularization in chick chorioallantoic membrane assay at 0.08-2 mg/mL. In the in vitro experiments, SIP-SII (0.8-500 μg/mL) significantly decreased the protein and mRNA expression of ICAM-1 and bFGF in SKOV3 and EA.hy926 cells, respectively. These results suggested that SIP-SII might suppress melanoma metastasis via the inhibition of the tumor adhesion mediated by ICAM-1 and the angiogenesis mediated by bFGF, as well as resulting in depression of the invasion and migration of carcinoma cells.

Hematopoietic effects and mechanisms of Fufang e׳jiao jiang on radiotherapy and chemotherapy-induced myelosuppressed mice.

ETHNOPHARMACOLOGICAL RELEVANCE Fufang e׳jiao jiang (FEJ), which has been widely used in clinic to replenish qi (vital energy) and nourish blood, is a famous traditional Chinese medicine formula made up of Colla corii asini (donkey-hide gelatin prepared by stewing and concentrating from the hide of Equus asinus Linnaeus.), Radix codonopsis pilosulae (the root of Codonopsis pilosula (Franch.) Nannf.), Radix ginseng rubra (the steamed and dried root of Panax ginseng C.A. Mey.), Fructus crataegi (the fruit of Crataegus pinnatifida Bunge) and Radix rehmanniae preparata (the steamed and sun dried tuber of Rehmannia glutinosa (Gaertn.) Libosch. ex Fisch. & C.A. Mey.). The present study aimed to investigate the hematopoietic effects of FEJ on myelosuppressed mice induced by radiotherapy and chemotherapy systematically and to explore the underlying hematopoietic regulation mechanisms. METHODS The myelosuppressed mouse model was induced by (60)Co radiation, cyclophosphamide and chloramphenicol. FEJ was then administered by i.g. at the dosages of 5, 10, or 20 mL/kg·d for 10d. The numbers of blood cells from peripheral blood and bone marrow nucleated cells (BMNC) were counted. Body weight and the thymus and spleen indices were also measured. The numbers of hemopoietic progenitor cells and colony-forming unit-fibroblast (CFU-F) were measured in vitro. The ratio of hematopoietic stem cells (HSC) in BMNC, cell cycle and apoptosis of BMNC were determined by flow cytometry. The histology of femoral bone was examined by H&E staining. The levels of transforming growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α), erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3) and interleukin-6 (IL-6) in serum were measured by ELISA. IL-1β, IL-3, IL-6 mRNA levels in spleen were detected by real-time quantitative PCR (RT-qPCR). In addition, bone marrow stromal cells (BMSC) were cultured in vitro followed by treatment with different doses of FEJ (2.5, 5, 10 μL/mL) for 48 h. Then the levels of cytokines (IL-6, SCF, GM-CSF) in the conditioned media and their mRNA levels in BMSC were determined by ELISA and RT-qPCR, respectively. RESULTS FEJ could significantly increase the numbers of peripheral blood cells and BMNC, and reverse the loss of body weight and the atrophy of thymus and spleen in a dose-dependent manner. The quantities of hemopoietic progenitor cells and CFU-F in bone marrow were also significantly increased in a dose-dependent manner after FEJ administration. A high-dose FEJ of 20 mL/kg·d could significantly increase the ratio of HSC in BMNC, promote bone marrow cells entering the proliferative cycle phase (S+G2/M) and prevent cells from proceeding to the apoptotic phase. FEJ could also improve the femoral bone marrow morphology. Furthermore, FEJ could increase the levels of GM-CSF and IL-3 and reduce the level of TGF-β in serum, and enhance the expressions of IL-1β and IL-3 mRNA in spleen. Lastly, the levels of cytokines (IL-6, SCF, GM-CSF) in the conditioned media and their mRNA levels in BMSC were elevated after treatment with FEJ. CONCLUSIONS FEJ was clearly confirmed to promote the recovery of bone marrow hemopoietic function in a myelosuppressed mouse model, which may be attributed to (i) improving bone marrow hematopoietic microenvironment; (ii) facilitating the cell proliferation and preventing BMNC from apoptosis; (iii) stimulating the expressions of IL-1β, IL-3, IL-6, SCF and GM-CSF and inhibiting the expression of TGF-β.

Recent Advance in Tumor-associated Carbohydrate Antigens (TACAs)-based Antitumor Vaccines

Cancer cells can be distinguished from normal cells by displaying aberrant levels and types of carbohydrate structures on their surfaces. These carbohydrate structures are known as tumor-associated carbohydrate antigens (TACAs). TACAs were considered as promising targets for the design of anticancer vaccines. Unfortunately, carbohydrates alone can only evoke poor immunogenicity because they are unable to induce T-cell-dependent immune responses, which is critical for cancer therapy. Moreover, immunotolerance and immunosuppression are easily induced by using natural occurring TACAs as antigens due to their endogenous property. This review summarizes the recent strategies to overcome these obstacles: (1) covalently coupling TACAs to proper carriers to improve immunogenicity, including clustered or multivalent conjugate vaccines, (2) coupling TACAs to T-cell peptide epitopes or the built-in adjuvant to form multicomponent glycoconjugate vaccines, and (3) developing vaccines based on chemically modified TACAs, which is combined with metabolic engineering of cancer cells.

Heparosan-Derived Heparan Sulfate/Heparin-Like Compounds: One Kind of Potential Therapeutic Agents

Heparan sulfate (HS) is a highly sulfated glycosaminoglycan and exists in all animal tissues. HS and heparin are very similar, except that heparin has higher level of sulfation and higher content of iduronic acid. Despite the fact that it is a century‐old drug, heparin remains as a top choice for treating thrombotic disorders. Pharmaceutical heparin is derived from porcine intestine or bovine lung via a long supply chain. This supply chain is vulnerable to the contamination of animal pathogens. Therefore, new methods for manufacturing heparin or heparin‐like substances devoid of animal tissues have been explored by many researchers, among which, modifications of heparosan, the capsular polysaccharide of Escherichia coli K5 strain, is one of the promising approaches. Heparosan has a structure similar to unmodified backbone of natural HS and heparin. It is feasible to obtain HS or heparin derivatives by modifying heparosan with chemical or enzymatic methods. These derivatives display different biological activities, such as anticoagulant, anti‐inflammatory, anticancer, and antiviral activities. This review focuses on the recent studies of synthesis, activity, and structure‐activity relationship of HS/heparin‐like derivatives prepared from heparosan.

Use of induction promoters to regulate hyaluronan synthase and UDP-glucose-6-dehydrogenase of Streptococcus zooepidemicus expression in Lactococcus lactis: a case study of the regulation mechanism of hyaluronic acid polymer.

Aims:  To determine the effects of the ratios of hyaluronan synthase expression level to precursor sugar UDP‐GlcA biosynthesis ability on the molecular weight (MW) of hyaluronic acid (HA) in recombinant Lactococcus lactis.

Intracellular transduction and potential of Tat PTD and its analogs: from basic drug delivery mechanism to application.

Introduction: It has been 20 years since the discovery of the membrane-translocating property of the HIV-1 transactivator of transcription (Tat) protein. The Tat protein transduction domain (Tat PTD) is a very promising tool for non-invasive cellular import of cargos and has been successfully applied to in vitro and in vivo delivery of different therapeutic agents for the treatment of many diseases. A growing number of reports on Tat PTD-mediated delivery have extensively revealed the mechanisms involved. Yet, due to the varied conditions used, the reports on the internalization mode of Tat PTD-cargo chimera are often varied. Areas covered: This article reviews the possible intracellular trafficking mechanisms of Tat PTD including its binding, cellular entry process, and the roles of participants of the cell membrane. The therapeutic applications via local administration, such as those for the treatment of skin, ocular, cardiac and cerebral diseases, are also reviewed. In addition, some novel systems built by different groups are elucidated, which are utilized to overcome the poor targeting efficiency of Tat PTD for the treatment of CNS diseases, cancer and other diseases via systemic administration. Expert opinion: With the development of targeting factors, such as antibodies, some cell targeting peptides and novel polymers, Tat PTD is expected to play a more efficient and/or better tolerated therapeutic role in the drug delivery field.